Parmax Pharma Limited announced unaudited standalone earnings results for the first quarter ended 30 June, 2021. For the quarter, the company reported revenue from operations of INR 17,348,202 against INR 22,731,325 a year ago. Total income from operations was INR 17,505,782 against INR 22,846,589 a year ago. Loss for the period was INR 4,350,870 against INR 9,960,182 a year ago. Basic loss per share was INR 1.16 against INR 2.66 a year ago.